Frequently Asked Questions

 

WHAT IS THE ONWARD STUDY?

ONWARD are clinical research studies for patients with metastatic cancer who are progesterone receptor positive (PR+).

How CAN PATIENTS FIND OUT IF THEY ARE PR+?

Progesterone receptor evaluation is typically performed during initial biopsy evaluation.  At this time, PR status is determined as well as other cancer subtypes, including estrogen receptor (ER) and HER2.

HaS THE INVESTIGATIONAL DRUG EVER BEEN GIVEN TO PATIENTS?

Yes.  Apristor, has already been given to patients in previous studies.  So far, 88 patients with different types of cancers have received Apristor.  Additionally, several hundred women have received Onapristone, the immediate release version of Apristor, in previous studies evaluating the drug's potential in breast cancer as well as a contraceptive.

HOW IS THE INVESTIGATIONAL DRUG BELIEVED TO WORK?

The investigational drug Apristor is administered as a pill.  The drug functions by preventing progesterone from binding to the progesterone receptor.  Context Therapeutics, the company who is studying Apristor, believes the drug may halt the growth of cancer cancer cells by preventing progesterone receptor from activating pro-survival pathways in PR+ tumors.

HOW IS APRISTOR GIVEN?

Patients take two 50 mg pills of Apristor in 12 hour intervals with or without food